{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,16]],"date-time":"2026-08-16T07:25:13Z","timestamp":1786865113900,"version":"build-2736575974"},"reference-count":93,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,8,16]],"date-time":"2026-08-16T00:00:00Z","timestamp":1786838400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,8,16]],"date-time":"2026-08-16T00:00:00Z","timestamp":1786838400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100005788","name":"Medical University of Vienna","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100005788","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["World J Urol"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>We aimed to systematically summarize data on efficacy of local salvage therapies for local recurrence of renal cell carcinoma (RCC).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We searched MEDLINE, Embase, Web of Science, CENTRAL, and Google Scholar through 05\/08\/2026, for studies on local salvage therapies for local recurrence of RCC following radical nephrectomy, partial nephrectomy, or ablation (PROSPERO: CRD42024623099). Meta-analyses were conducted using random-effects models. Risk of bias (RoB) was assessed using ROBINS-I.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Forty-seven studies comprising 2039 patients were included (45 retrospective). Patients recurring after primary ablation predominantly presented with new renal masses, and were managed with repeat ablation (6 studies,\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u2009193) or salvage surgery (3 studies,\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u200948), both yielding low recurrence rates. Local recurrences (M0) after primary partial nephrectomy (PN), most often in patients with pT1 disease, were treated with repeat PN, radical nephrectomy (RN), or ablation (15 studies,\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u2009562), with heterogeneous outcomes across modalities, ranging from low recurrence rates to predominantly distant metastatic failure. In contrast, recurrences after primary RN (12 studies,\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u2009564) occurred in a population with primarily locally advanced disease (pT3-4) and outcomes were notably worse, driven by distant progression. Four studies used radiotherapy in salvage setting, with heterogeneous methods and outcomes. Majority of studies were assessed moderate RoB, 16 studies assessed as serious, predominantly due to bias in participant selection.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Efficacy of local salvage therapies for RCC recurrence is influenced by the primary treatment and histopathological advancement of primary disease. Repeat ablation provides favorable outcomes, while recurrences after PN can be managed with repeat surgery or ablation, with heterogeneous results (from low recurrence rates to frequent distant metastases). Post-RN patients, often with initially advanced disease, have worse prognosis with approximately two-thirds experiencing progression by three years, primarily due to distant metastases. Overall, quality of evidence remains low. There is critical need for expert consensus on quality indicators for locally recurrent RCC care and for prospective registries with standardized outcome reporting.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s00345-026-06684-8","type":"journal-article","created":{"date-parts":[[2026,8,16]],"date-time":"2026-08-16T06:29:51Z","timestamp":1786861791000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Salvage therapies for local recurrence of renal cell carcinoma: a systematic review and meta-analysis"],"prefix":"10.1007","volume":"44","author":[{"given":"Agata","family":"Suleja","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmed R.","family":"Alfarhan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcin","family":"Miszczyk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Riccardo","family":"Campi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hussain Albin","family":"Hamdhah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniele","family":"Amparore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giulio","family":"Francolini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Navid","family":"Roessler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keiichiro","family":"Miyajima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shota","family":"Inoue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Felix","family":"L\u00fcbbersmeyer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdulrahman A.","family":"Alhazeem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pawe\u0142","family":"Rajwa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Axel","family":"Bex","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandro","family":"Volpe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Piet","family":"Ost","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shahrokh F.","family":"Shariat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,8,16]]},"reference":[{"issue":"6","key":"6684_CR1","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1016\/j.eururo.2025.02.020","volume":"87","author":"A Bex","year":"2025","unstructured":"Bex A, Ghanem YA, Albiges L et al (2025) European Association of Urology Guidelines on Renal Cell Carcinoma: The 2025 Update. Eur Urol 87(6):683\u2013696. https:\/\/doi.org\/10.1016\/j.eururo.2025.02.020","journal-title":"Eur Urol"},{"key":"6684_CR2","unstructured":"nccn.org\/professionals\/physician_gls\/pdf\/kidney.pdf . Accessed May 10, 2026. https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/kidney.pdf"},{"issue":"2","key":"6684_CR3","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1080\/02656736.2019.1647352","volume":"36","author":"D Filippiadis","year":"2019","unstructured":"Filippiadis D, Mauri G, Marra P, Charalampopoulos G, Gennaro N, De Cobelli F (2019) Percutaneous ablation techniques for renal cell carcinoma: current status and future trends. Int J Hyperthermia 36(2):21\u201330. https:\/\/doi.org\/10.1080\/02656736.2019.1647352","journal-title":"Int J Hyperthermia"},{"issue":"3","key":"6684_CR4","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1016\/j.euo.2018.05.001","volume":"1","author":"MC Mir","year":"2018","unstructured":"Mir MC, Capitanio U, Bertolo R et al (2018) Role of Active Surveillance for Localized Small Renal Masses. Eur Urol Oncol 1(3):177\u2013187. https:\/\/doi.org\/10.1016\/j.euo.2018.05.001","journal-title":"Eur Urol Oncol"},{"key":"6684_CR5","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1007\/978-1-60327-149-3_17","volume-title":"Clinical Management of Renal Tumors","author":"BK McNeil","year":"2008","unstructured":"McNeil BK, Campbell SC (2008) Local Recurrence of Renal Cell Carcinoma: Management. In: Bukowski RM, Novick AC (eds) Clinical Management of Renal Tumors. Humana Press, pp 275\u2013292. https:\/\/doi.org\/10.1007\/978-1-60327-149-3_17"},{"key":"6684_CR6","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1016\/j.urology.2021.03.038","volume":"154","author":"S Ray","year":"2021","unstructured":"Ray S, Cheaib JG, Biles MJ et al (2021) Local and Regional Recurrences of Clinically Localized Renal Cell Carcinoma after Nephrectomy: A 15 Year Institutional Experience with Prognostic Features and Oncologic Outcomes. Urology 154:201\u2013207. https:\/\/doi.org\/10.1016\/j.urology.2021.03.038","journal-title":"Urology"},{"issue":"3","key":"6684_CR7","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1093\/jjco\/hyab201","volume":"52","author":"N Nakajima","year":"2022","unstructured":"Nakajima N, Miyajima A, Shinohara N et al (2022) Risk factors for recurrence after operation in patients with pT1a renal cell carcinoma: sub-analysis of the multi-institutional national database of the Japanese Urological Association. Jpn J Clin Oncol 52(3):274\u2013280. https:\/\/doi.org\/10.1093\/jjco\/hyab201","journal-title":"Jpn J Clin Oncol"},{"issue":"8","key":"6684_CR8","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1002\/bco2.375","volume":"5","author":"G Bencina","year":"2024","unstructured":"Bencina G, Billeskov R, Bak R et al (2024) Recurrence patterns following nephrectomy for renal cell carcinoma in a Danish nationwide cohort. BJUI Compass 5(8):791\u2013798. https:\/\/doi.org\/10.1002\/bco2.375","journal-title":"BJUI Compass"},{"issue":"1","key":"6684_CR9","doi-asserted-by":"publisher","DOI":"10.1007\/s00345-024-05172-1","volume":"42","author":"AK Rosenblad","year":"2024","unstructured":"Rosenblad AK, Hashim BM, Lindblad P, Ljungberg B, the National Swedish Kidney Cancer Register Steering Committee (2024) Recurrences after nephron-sparing treatments of renal cell carcinoma: a competing risk analysis. World J Urol 42(1):474. https:\/\/doi.org\/10.1007\/s00345-024-05172-1","journal-title":"World J Urol"},{"issue":"19","key":"6684_CR10","doi-asserted-by":"publisher","DOI":"10.3390\/cancers16193276","volume":"16","author":"A Suleja","year":"2024","unstructured":"Suleja A, Bilski M, Laukhtina E et al (2024) Stereotactic body radiotherapy (SBRT) for the treatment of primary localized renal cell carcinoma: a systematic review and meta-analysis. Cancers 16(19):3276. https:\/\/doi.org\/10.3390\/cancers16193276","journal-title":"Cancers"},{"issue":"6","key":"6684_CR11","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1016\/j.euo.2018.06.007","volume":"1","author":"MC Kriegmair","year":"2018","unstructured":"Kriegmair MC, Bertolo R, Karakiewicz PI et al (2018) Systematic Review of the Management of Local Kidney Cancer Relapse. Eur Urol Oncol 1(6):512\u2013523. https:\/\/doi.org\/10.1016\/j.euo.2018.06.007","journal-title":"Eur Urol Oncol"},{"key":"6684_CR12","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.n71","author":"P Mj","year":"2021","unstructured":"Mj P, Je M, Pm B et al (2021) The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. https:\/\/doi.org\/10.1136\/bmj.n71","journal-title":"BMJ"},{"key":"6684_CR13","doi-asserted-by":"publisher","unstructured":"Shea BJ, Reeves BC, Wells G et al (2017) AMSTAR 2: a critical appraisal tool for systematic reviews that include randomised or non-randomised studies of healthcare interventions, or both. Published online September 21. https:\/\/doi.org\/10.1136\/bmj.j4008","DOI":"10.1136\/bmj.j4008"},{"issue":"4","key":"6684_CR14","doi-asserted-by":"publisher","first-page":"531","DOI":"10.5195\/jmla.2018.283","volume":"106","author":"WM Bramer","year":"2018","unstructured":"Bramer WM, de Jonge GB, Rethlefsen ML, Mast F, Kleijnen J (2018) A systematic approach to searching: an efficient and complete method to develop literature searches. J Med Libr Assoc 106(4):531\u2013541. https:\/\/doi.org\/10.5195\/jmla.2018.283","journal-title":"J Med Libr Assoc"},{"issue":"1","key":"6684_CR15","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1186\/s13643-016-0384-4","volume":"5","author":"M Ouzzani","year":"2016","unstructured":"Ouzzani M, Hammady H, Fedorowicz Z, Elmagarmid A (2016) Rayyan\u2014a web and mobile app for systematic reviews. Syst Rev 5(1):210. https:\/\/doi.org\/10.1186\/s13643-016-0384-4","journal-title":"Syst Rev"},{"key":"6684_CR16","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.i4919","author":"JA Sterne","year":"2016","unstructured":"Sterne JA, Hern\u00e1n MA, Reeves BC et al (2016) ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions. BMJ. https:\/\/doi.org\/10.1136\/bmj.i4919","journal-title":"BMJ"},{"key":"6684_CR17","doi-asserted-by":"publisher","unstructured":"Cumpston M, Li T, Page MJ et al (2026) Updated guidance for trusted systematic reviews: a new edition of the Cochrane Handbook for Systematic Reviews of Interventions | Cochrane Library. Accessed May 10. https:\/\/www.cochranelibrary.com\/cdsr\/doi\/https:\/\/doi.org\/10.1002\/14651858.ED000142\/full","DOI":"10.1002\/14651858.ED000142\/full"},{"key":"6684_CR18","unstructured":"WebPlotDigitizer - (2026) Copyright 2010\u20132024 Ankit Rohatgi. Accessed May 10. https:\/\/automeris.io\/wpd\/?v=5_2"},{"issue":"1","key":"6684_CR19","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1016\/j.euf.2021.02.007","volume":"8","author":"M Brassier","year":"2022","unstructured":"Brassier M, Khene ZE, Bernhard JC et al (2022) Percutaneous Ablation Versus Surgical Resection for Local Recurrence Following Partial Nephrectomy for Renal Cell Cancer: A Propensity Score Analysis (REPART Study-UroCCR 71). Eur Urol Focus 8(1):210\u2013216. https:\/\/doi.org\/10.1016\/j.euf.2021.02.007","journal-title":"Eur Urol Focus"},{"key":"6684_CR20","doi-asserted-by":"publisher","first-page":"S1327","DOI":"10.1016\/j.annonc.2025.08.3261","volume":"36","author":"R Liu","year":"2025","unstructured":"Liu R, Liu Y, Zhang Z et al (2025) 2648P Phase II clinical study of the safety and efficacy of Sintilimab in combination with Axitinib and stereotactic radiotherapy in the treatment of local-regional recurrent renal cell carcinoma. Ann Oncol 36:S1327. https:\/\/doi.org\/10.1016\/j.annonc.2025.08.3261","journal-title":"Ann Oncol"},{"issue":"5","key":"6684_CR21","doi-asserted-by":"publisher","first-page":"926","DOI":"10.1016\/S0090-4295(02)02582-7","volume":"61","author":"\u00c7 G\u00f6\u011f\u00fc\u015f","year":"2003","unstructured":"G\u00f6\u011f\u00fc\u015f \u00c7, Baltaci S, Bed\u00fck Y, \u015eahinli S, K\u00fcpeli S, G\u00f6\u011f\u00fc\u015f O (2003) Isolated local recurrence of renal cell carcinoma after radical nephrectomy: experience with 10 cases. Urology 61(5):926\u2013929. https:\/\/doi.org\/10.1016\/S0090-4295(02)02582-7","journal-title":"Urology"},{"issue":"4","key":"6684_CR22","doi-asserted-by":"publisher","first-page":"4","DOI":"10.48193\/4s2h3424","volume":"84","author":"GAF Candia","year":"2024","unstructured":"Candia GAF, Camean J, Jaunarena J, Chemi J, Bachur RV, Villoldo G (2024) Complete laparoscopic management of locally recurrent renal cell carcinoma after radical nephrectomy. Rev Mex Urol 84(4):4. https:\/\/doi.org\/10.48193\/4s2h3424","journal-title":"Rev Mex Urol"},{"issue":"2","key":"6684_CR23","doi-asserted-by":"publisher","first-page":"315.e1","DOI":"10.1016\/j.clgc.2022.10.010","volume":"21","author":"J Huang","year":"2023","unstructured":"Huang J, Wang Y, Zhang C et al (2023) Surgical management and oncologic outcomes for local retroperitoneal recurrence of renal cell carcinoma after radical nephrectomy. Clin Genitourin Cancer 21(2):315.e1-315.e7. https:\/\/doi.org\/10.1016\/j.clgc.2022.10.010","journal-title":"Clin Genitourin Cancer"},{"issue":"3","key":"6684_CR24","doi-asserted-by":"publisher","first-page":"111.e27","DOI":"10.1016\/j.urolonc.2021.11.028","volume":"40","author":"M Stan\u00edk","year":"2022","unstructured":"Stan\u00edk M, Poprach A, Littnerov\u00e1 S et al (2022) Oncological outcomes of surgery for isolated retroperitoneal recurrence in renal cancer patients after radical nephrectomy. Urol Oncol 40(3):111.e27-111.e34. https:\/\/doi.org\/10.1016\/j.urolonc.2021.11.028","journal-title":"Urol Oncol"},{"issue":"23","key":"6684_CR25","doi-asserted-by":"publisher","first-page":"4430","DOI":"10.1002\/cam4.4790","volume":"11","author":"Y Liu","year":"2022","unstructured":"Liu Y, Zhang X, Ma H et al (2022) Locoregional recurrence after nephrectomy for localized renal cell carcinoma: Feasibility and outcomes of different treatment modalities. Cancer Med 11(23):4430\u20134439. https:\/\/doi.org\/10.1002\/cam4.4790","journal-title":"Cancer Med"},{"issue":"2","key":"6684_CR26","doi-asserted-by":"publisher","first-page":"42.e7","DOI":"10.1016\/j.urolonc.2019.10.004","volume":"38","author":"A Romeo","year":"2020","unstructured":"Romeo A, Garcia Marchi\u00f1ena P, Jurado AM, Gueglio G (2020) Renal fossa recurrence after radical nephrectomy: current management, and oncological outcomes. Urol Oncol Semin Orig Investig 38(2):42.e7-42.e12. https:\/\/doi.org\/10.1016\/j.urolonc.2019.10.004","journal-title":"Urol Oncol Semin Orig Investig"},{"issue":"1","key":"6684_CR27","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.urolonc.2017.08.021","volume":"36","author":"R Herout","year":"2018","unstructured":"Herout R, Graff J, Borkowetz A et al (2018) Surgical resection of locally recurrent renal cell carcinoma after nephrectomy: Oncological outcome and predictors of survival. Urol Oncol Semin Orig Investig 36(1):11. https:\/\/doi.org\/10.1016\/j.urolonc.2017.08.021","journal-title":"Urol Oncol Semin Orig Investig"},{"issue":"2","key":"6684_CR28","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1016\/j.juro.2015.02.2943","volume":"194","author":"AZ Thomas","year":"2015","unstructured":"Thomas AZ, Adibi M, Borregales LD et al (2015) Surgical Management of Local Retroperitoneal Recurrence of Renal Cell Carcinoma after Radical Nephrectomy. J Urol 194(2):316\u2013322. https:\/\/doi.org\/10.1016\/j.juro.2015.02.2943","journal-title":"J Urol"},{"issue":"3","key":"6684_CR29","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1016\/j.jnci.2014.05.003","volume":"26","author":"IS Fayek","year":"2014","unstructured":"Fayek IS, Habashy HF, Habashy NF (2014) Isolated loco-regional recurrence after radical nephrectomy for renal cell carcinoma: A study of 22patients. J Egypt Natl Cancer Inst 26(3):161\u2013166. https:\/\/doi.org\/10.1016\/j.jnci.2014.05.003","journal-title":"J Egypt Natl Cancer Inst"},{"key":"6684_CR30","doi-asserted-by":"publisher","DOI":"10.1016\/j.juro.2009.01.043","author":"V Margulis","year":"2009","unstructured":"Margulis V, McDonald M, Tamboli P, Swanson DA, Wood CG (2009) Predictors of Oncological Outcome After Resection of Locally Recurrent Renal Cell Carcinoma. J Urol Published online May. https:\/\/doi.org\/10.1016\/j.juro.2009.01.043","journal-title":"J Urol Published online May"},{"issue":"5","key":"6684_CR31","doi-asserted-by":"publisher","first-page":"933","DOI":"10.1111\/j.1464-410X.2006.06076.x","volume":"97","author":"JJ Bruno","year":"2006","unstructured":"Bruno JJ, Snyder ME, Motzer RJ, Russo P (2006) Renal cell carcinoma local recurrences: impact of surgical treatment and concomitant metastasis on survival. BJU Int 97(5):933\u2013938. https:\/\/doi.org\/10.1111\/j.1464-410X.2006.06076.x","journal-title":"BJU Int"},{"issue":"4","key":"6684_CR32","doi-asserted-by":"publisher","first-page":"522","DOI":"10.1111\/j.1464-410X.2005.05331.x","volume":"95","author":"SS Sandhu","year":"2005","unstructured":"Sandhu SS, Symes A, A\u2019hern R et al (2005) Surgical excision of isolated renal-bed recurrence after radical nephrectomy for renal cell carcinoma. BJU Int 95(4):522\u2013525. https:\/\/doi.org\/10.1111\/j.1464-410X.2005.05331.x","journal-title":"BJU Int"},{"issue":"1","key":"6684_CR33","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1097\/JS9.0000000000001917","volume":"111","author":"W Ma","year":"2025","unstructured":"Ma W, Xu W, Meng J et al (2025) Reoperation for ipsilateral local recurrence following prior nephron-sparing surgery: innovative surgical insights from a high-volume urological center with cross-sectional study. Int J Surg 111(1):171\u2013177. https:\/\/doi.org\/10.1097\/JS9.0000000000001917","journal-title":"Int J Surg"},{"issue":"4","key":"6684_CR34","doi-asserted-by":"publisher","first-page":"1579","DOI":"10.1007\/s11701-023-01538-6","volume":"17","author":"KE Okhawere","year":"2023","unstructured":"Okhawere KE, Grauer R, Zuluaga L et al (2023) Operative and oncological outcomes of salvage robotic radical and partial nephrectomy: a multicenter experience. J Robot Surg 17(4):1579\u20131585. https:\/\/doi.org\/10.1007\/s11701-023-01538-6","journal-title":"J Robot Surg"},{"key":"6684_CR35","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1016\/j.euros.2023.09.007","volume":"57","author":"F Di Maida","year":"2023","unstructured":"Di Maida F, Grosso AA, Campi R et al (2023) Redo partial nephrectomy for local recurrence after previous nephron-sparing surgery. Surgical insights and oncologic results from a high-volume robotic center. Eur Urol Open Sci 57:84\u201390. https:\/\/doi.org\/10.1016\/j.euros.2023.09.007","journal-title":"Eur Urol Open Sci"},{"issue":"10","key":"6684_CR36","doi-asserted-by":"publisher","first-page":"434.e17","DOI":"10.1016\/j.urolonc.2023.07.010","volume":"41","author":"J Huang","year":"2023","unstructured":"Huang J, Su R, Zhang C et al (2023) Comparative analysis of salvage partial nephrectomy versus radical nephrectomy after the failure of initial partial nephrectomy. Urol Oncol 41(10):434.e17-434.e25. https:\/\/doi.org\/10.1016\/j.urolonc.2023.07.010","journal-title":"Urol Oncol"},{"key":"6684_CR37","doi-asserted-by":"publisher","first-page":"S500","DOI":"10.1016\/S0302-2838(23)00392-5","volume":"83","author":"A Brassetti","year":"2023","unstructured":"Brassetti A, Anceschi U, Bove AM et al (2023) A0343 - Redo robotic partial nephrectomy for recurrent renal tumors: Single high-volume center experience. Eur Urol 83:S500\u2013S501. https:\/\/doi.org\/10.1016\/S0302-2838(23)00392-5","journal-title":"Eur Urol"},{"key":"6684_CR38","doi-asserted-by":"publisher","DOI":"10.1016\/j.juro.2016.02.185","author":"A Antonelli","year":"2016","unstructured":"Antonelli A, Sodano M, Furlan M et al (2016) MP41-18 pathogenesis, features and prognosis of renal relapse after partial nephrectomy. J Urol. https:\/\/doi.org\/10.1016\/j.juro.2016.02.185","journal-title":"J Urol"},{"key":"6684_CR39","doi-asserted-by":"publisher","DOI":"10.1016\/j.juro.2008.03.030","author":"A Johnson","year":"2018","unstructured":"Johnson A, Sudarshan S, Liu J, Linehan WM, Pinto PA, Bratslavsky G (2018) Feasibility and outcomes of repeat partial nephrectomy. J Urol. https:\/\/doi.org\/10.1016\/j.juro.2008.03.030","journal-title":"J Urol"},{"key":"6684_CR40","doi-asserted-by":"publisher","DOI":"10.1245\/s10434-026-19960-z","author":"W Zhou","year":"2026","unstructured":"Zhou W, Guan H, Yao J et al (2026) Pathologic upstaging in local recurrence after partial nephrectomy: distinct biologic behavior and clinical prognosis of original-site versus non\u2013original-site recurrence. Ann Surg Oncol. https:\/\/doi.org\/10.1245\/s10434-026-19960-z","journal-title":"Ann Surg Oncol"},{"key":"6684_CR41","doi-asserted-by":"publisher","first-page":"A437","DOI":"10.1089\/end.2024.38524.abstracts","volume":"38","author":"A Hemal","year":"2024","unstructured":"Hemal A, Refugia J (2024) Robot Assisted Salvage Partial Nephrectomy: A Feasible Option for Management of Tumor Recurrences After Cryoablation or Radiofrequency Ablation. J Endourol 38:A437. https:\/\/doi.org\/10.1089\/end.2024.38524.abstracts","journal-title":"J Endourol"},{"key":"6684_CR42","doi-asserted-by":"publisher","DOI":"10.23736\/S2724-6051.22.04693-6","author":"G Margue","year":"2022","unstructured":"Margue G, Michiels C, Allenet C et al (2022) Feasibility of salvage robotic partial nephrectomy after ablative treatment failure (UroCCR-62 study). Minerva Urol Nefrol. https:\/\/doi.org\/10.23736\/S2724-6051.22.04693-6","journal-title":"Minerva Urol Nefrol"},{"issue":"3","key":"6684_CR43","doi-asserted-by":"publisher","first-page":"594","DOI":"10.1016\/j.juro.2015.09.078","volume":"195","author":"JA Jim\u00e9nez","year":"2016","unstructured":"Jim\u00e9nez JA, Zhang Z, Zhao J et al (2016) Surgical Salvage of Thermal Ablation Failures for Renal Cell Carcinoma. J Urol 195(3):594\u2013600. https:\/\/doi.org\/10.1016\/j.juro.2015.09.078","journal-title":"J Urol"},{"issue":"19","key":"6684_CR44","doi-asserted-by":"publisher","DOI":"10.3390\/cancers17193269","volume":"17","author":"A Porreca","year":"2025","unstructured":"Porreca A, Marino F, De Marchi D et al (2025) Local recurrence after nephron surgery: what to do? An Italian multicentric registry. Cancers (Basel) 17(19):3269. https:\/\/doi.org\/10.3390\/cancers17193269","journal-title":"Cancers (Basel)"},{"issue":"1","key":"6684_CR45","doi-asserted-by":"publisher","first-page":"15","DOI":"10.21294\/1814-4861-2025-24-1-15-28","volume":"24","author":"MY Gaas","year":"2025","unstructured":"Gaas MY, Kaprin AD, Kostin AA et al (2025) Surgical treatment of local renal cell carcinoma recurrence. Surgical aspects and oncological results. Sibirskii Onkologicheskii Zhurnal 24(1):15\u201328. https:\/\/doi.org\/10.21294\/1814-4861-2025-24-1-15-28","journal-title":"Sibirskii Onkologicheskii Zhurnal"},{"key":"6684_CR46","doi-asserted-by":"publisher","DOI":"10.1097\/JU.0000000000003263.09","author":"S Saini","year":"2023","unstructured":"Saini S, O\u2019Rourke T, Thakker P, Hemal A, V05-09 ROBOT-ASSISTED PARTIAL NEPHRECTOMY FOR NEW OR RECURRENT TUMOR IN PATIENT WITH PRIOR PARTIAL NEPHRECTOMY OR TUMOR ABLATION (2023) J Urol Published online April. https:\/\/doi.org\/10.1097\/JU.0000000000003263.09","journal-title":"J Urol Published online April"},{"issue":"10","key":"6684_CR47","doi-asserted-by":"publisher","first-page":"1296","DOI":"10.1089\/end.2021.0954","volume":"36","author":"AT Beksac","year":"2022","unstructured":"Beksac AT, Carbonara U, Abou Zeinab M et al (2022) Redo Robotic Partial Nephrectomy for Recurrent Renal Tumors: A Multi-Institutional Analysis. J Endourol 36(10):1296\u20131301. https:\/\/doi.org\/10.1089\/end.2021.0954","journal-title":"J Endourol"},{"issue":"9","key":"6684_CR48","doi-asserted-by":"publisher","first-page":"739.e1","DOI":"10.1016\/j.urolonc.2020.06.006","volume":"38","author":"MP Barboza","year":"2020","unstructured":"Barboza MP, Speir RW, Boris RS et al (2020) Understanding the role of salvage lymphadenectomy in node only recurrences after nephrectomy for renal cell carcinoma. Urol Oncol 38(9):739.e1-739.e8. https:\/\/doi.org\/10.1016\/j.urolonc.2020.06.006","journal-title":"Urol Oncol"},{"key":"6684_CR49","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1016\/j.urology.2020.07.060","volume":"145","author":"R Ghandour","year":"2020","unstructured":"Ghandour R, Miranda AF, Singla N et al (2020) Feasibility and Safety of Robotic Excision of Ipsilateral Retroperitoneal Recurrence After Nephrectomy for Renal Cell Carcinoma. Urology 145:159\u2013165. https:\/\/doi.org\/10.1016\/j.urology.2020.07.060","journal-title":"Urology"},{"key":"6684_CR50","doi-asserted-by":"publisher","DOI":"10.1016\/j.juro.2017.02.521","author":"P Capogrosso","year":"2017","unstructured":"Capogrosso P, Barret E, Nunes-Silva I et al (2017) MP16-15 NATURAL HISTORY OF SURGICALLY TREATED LOCAL RECURRENCE AFTER NEPHRECTOMY. J Urol Published online April. https:\/\/doi.org\/10.1016\/j.juro.2017.02.521","journal-title":"J Urol Published online April"},{"issue":"4","key":"6684_CR51","doi-asserted-by":"publisher","first-page":"e379","DOI":"10.1016\/j.clgc.2016.01.012","volume":"14","author":"Y Du","year":"2016","unstructured":"Du Y, Gr\u00fcllich C, Hadaschik B, Hatiboglu G, Hohenfellner M, Pahernik S (2016) Local Recurrence After Curative Surgical Treatment of Renal Cell Cancer: A Study of 91 Patients. Clin Genitourin Cancer 14(4):e379\u2013e385. https:\/\/doi.org\/10.1016\/j.clgc.2016.01.012","journal-title":"Clin Genitourin Cancer"},{"issue":"1","key":"6684_CR52","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1590\/S1677-5538.IBJU.2015.01.20","volume":"41","author":"FG Abarzua-Cabezas","year":"2015","unstructured":"Abarzua-Cabezas FG, Sverrisson E, De La Cruz R, Spiess PE, Haddock P, Sexton WJ (2015) Oncological and functional outcomes of salvage renal surgery following failed primary intervention for renal cell carcinoma. Int Braz J Urol Off J Braz Soc Urol 41(1):147\u2013154. https:\/\/doi.org\/10.1590\/S1677-5538.IBJU.2015.01.20","journal-title":"Int Braz J Urol Off J Braz Soc Urol"},{"issue":"1003","key":"6684_CR53","doi-asserted-by":"publisher","first-page":"A1","DOI":"10.1016\/j.urology.2011.07.754","volume":"2088","author":"P Riedl","year":"2011","unstructured":"Riedl P, Habl, Hohenfellner (2011) UP-01.204 Surgery\u2009+\u2009Intraoperative Radiotherapy (IORT) + Additive External Beam Radiation: A Promising Option for Treatment of Locally Recurrent Renal Cell Carcinoma (RCC)? Urology 2088(1003):A1. https:\/\/doi.org\/10.1016\/j.urology.2011.07.754","journal-title":"Urology"},{"key":"6684_CR54","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.693831","volume":"11","author":"SH Kim","year":"2021","unstructured":"Kim SH, Choi MG, Shin JH, Kim YA, Chung J (2021) A real-world, population-based retrospective analysis of therapeutic survival for recurrent localized renal cell carcinoma after nephrectomy. Front Oncol 11:693831. https:\/\/doi.org\/10.3389\/fonc.2021.693831","journal-title":"Front Oncol"},{"issue":"7","key":"6684_CR55","doi-asserted-by":"publisher","first-page":"444.e1","DOI":"10.1016\/j.urolonc.2025.03.018","volume":"43","author":"C Vaccaro","year":"2025","unstructured":"Vaccaro C, Mistretta FA, Piccinelli ML et al (2025) Thermal ablation for local tumor recurrence after previous partial nephrectomy: perioperative and oncological outcomes. Urol Oncol 43(7):444.e1-444.e10. https:\/\/doi.org\/10.1016\/j.urolonc.2025.03.018","journal-title":"Urol Oncol"},{"issue":"3","key":"6684_CR56","doi-asserted-by":"publisher","first-page":"S119","DOI":"10.1016\/j.jvir.2019.12.315","volume":"31","author":"M Abdelsalam","year":"2020","unstructured":"Abdelsalam M, Sabir S, Hudspeth T et al (2020) 3:27 PM Abstract 267 Efficacy of percutaneous image-guided thermal ablation for renal cell carcinoma following ipsilateral partial nephrectomy. J Vasc Interv Radiol 31(3):S119\u2013S120. https:\/\/doi.org\/10.1016\/j.jvir.2019.12.315","journal-title":"J Vasc Interv Radiol"},{"issue":"11","key":"6684_CR57","doi-asserted-by":"publisher","first-page":"1743","DOI":"10.1007\/s00270-018-1976-2","volume":"41","author":"W Zhou","year":"2018","unstructured":"Zhou W, Herwald SE, Uppot RN, Arellano RS (2018) Image-Guided Thermal Ablation for Non-resectable Recurrence of Renal Cell Cancer Following Nephrectomy: Clinical Experience with Eleven Patients. Cardiovasc Intervent Radiol 41(11):1743\u20131750. https:\/\/doi.org\/10.1007\/s00270-018-1976-2","journal-title":"Cardiovasc Intervent Radiol"},{"issue":"5","key":"6684_CR58","doi-asserted-by":"publisher","first-page":"686","DOI":"10.1016\/j.urolonc.2011.05.008","volume":"31","author":"B Yang","year":"2013","unstructured":"Yang B, Autorino R, Remer EM et al (2013) Probe ablation as salvage therapy for renal tumors in von Hippel-Lindau patients: The Cleveland Clinic experience with 3 years follow-up. Urol Oncol Semin Orig Investig 31(5):686\u2013692. https:\/\/doi.org\/10.1016\/j.urolonc.2011.05.008","journal-title":"Urol Oncol Semin Orig Investig"},{"issue":"4","key":"6684_CR59","doi-asserted-by":"publisher","first-page":"483","DOI":"10.20452\/wiitm.2024.17904","volume":"19","author":"W Krajewski","year":"2024","unstructured":"Krajewski W, Guzi\u0144ski M, Tomczak W et al (2024) Percutaneous cryoablation of kidney tumors after partial nephrectomy. Videosurg Miniinvasive Tech 19(4):483\u2013488. https:\/\/doi.org\/10.20452\/wiitm.2024.17904","journal-title":"Videosurg Miniinvasive Tech"},{"key":"6684_CR60","doi-asserted-by":"publisher","DOI":"10.1097\/JU.0000000000003345.06","author":"A Das","year":"2023","unstructured":"Das A, Shapiro D, Borza T et al (2023) PD40-06 Comparing oncologic outcomes between surgery and microwave ablation for renal masses between 3 and 7 CM. J Urol. https:\/\/doi.org\/10.1097\/JU.0000000000003345.06","journal-title":"J Urol"},{"issue":"2","key":"6684_CR61","doi-asserted-by":"publisher","first-page":"1","DOI":"10.15586\/jkcvhl.2020.133","volume":"7","author":"J Loloi","year":"2020","unstructured":"Loloi J, Shingleton WB, Nakada SY et al (2020) Management of Residual or Recurrent Disease Following Thermal Ablation of Renal Cortical Tumors. J Kidney Cancer VHL 7(2):1\u20135. https:\/\/doi.org\/10.15586\/jkcvhl.2020.133","journal-title":"J Kidney Cancer VHL"},{"issue":"11","key":"6684_CR62","doi-asserted-by":"publisher","first-page":"909","DOI":"10.1089\/end.2019.0444","volume":"33","author":"MO Sundelin","year":"2019","unstructured":"Sundelin MO, Lagerveld B, Ismail M, Keeley FX, Nielsen TK (2019) Repeated Cryoablation as Treatment Modality After Failure of Primary Renal Cryoablation: A European Registry for Renal Cryoablation Multinational Analysis. J Endourol 33(11):909\u2013913. https:\/\/doi.org\/10.1089\/end.2019.0444","journal-title":"J Endourol"},{"key":"6684_CR63","doi-asserted-by":"publisher","unstructured":"Yanagisawa T, Miki J, Sano T (2023) PD51-11 utility of salvage percutaneous cryoablation for locally recurrence rcc after primary cryoablation. J Urol. Published online April 2019. Accessed March 13, 2025. https:\/\/www.auajournals.org\/doi\/https:\/\/doi.org\/10.1097\/01.JU.0000556955.92159.54","DOI":"10.1097\/01.JU.0000556955.92159.54"},{"key":"6684_CR64","doi-asserted-by":"publisher","first-page":"A281","DOI":"10.1089\/end.2017.29029.abstracts","volume":"31","author":"R Van Der Vijgh","year":"2017","unstructured":"Van Der Vijgh R, Van Montauban A, Lagerveld B, Sandkuyl R (2017) The course of recurrence following cryoablation for renal tumors. J Endourol 31:A281. https:\/\/doi.org\/10.1089\/end.2017.29029.abstracts","journal-title":"J Endourol"},{"issue":"6","key":"6684_CR65","doi-asserted-by":"publisher","first-page":"632","DOI":"10.1089\/end.2016.0088","volume":"30","author":"Z Okhunov","year":"2016","unstructured":"Okhunov Z, Chamberlin J, Moreira DM et al (2016) Salvage Percutaneous Cryoablation for Locally Recurrent Renal-Cell Carcinoma After Primary Cryoablation. J Endourol 30(6):632\u2013637. https:\/\/doi.org\/10.1089\/end.2016.0088","journal-title":"J Endourol"},{"issue":"1","key":"6684_CR66","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1016\/j.juro.2008.03.046","volume":"180","author":"CT Nguyen","year":"2008","unstructured":"Nguyen CT, Lane BR, Kaouk JH et al (2008) Surgical Salvage of Renal Cell Carcinoma Recurrence After Thermal Ablative Therapy. J Urol 180(1):104\u2013109. https:\/\/doi.org\/10.1016\/j.juro.2008.03.046","journal-title":"J Urol"},{"issue":"1","key":"6684_CR67","doi-asserted-by":"publisher","first-page":"66.e19","DOI":"10.1016\/j.urolonc.2025.08.005","volume":"44","author":"C Pettenati","year":"2026","unstructured":"Pettenati C, Bernhard JC, Khene ZE et al (2026) Peritoneal recurrence following nephrectomy for localized renal cancer: a multicenter European real-world analysis of incidence, pattern and treatment (PEMET study\u2013UroCCR 124). Urol Oncol 44(1):66.e19-66.e26. https:\/\/doi.org\/10.1016\/j.urolonc.2025.08.005","journal-title":"Urol Oncol"},{"issue":"20","key":"6684_CR68","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14205069","volume":"14","author":"S Kirste","year":"2022","unstructured":"Kirste S, R\u00fchle A, Zschiedrich S et al (2022) Stereotactic body radiotherapy for renal cell carcinoma in patients with Von Hippel\u2013Lindau disease\u2014results of a prospective trial. Cancers (Basel) 14(20):5069. https:\/\/doi.org\/10.3390\/cancers14205069","journal-title":"Cancers (Basel)"},{"issue":"8","key":"6684_CR69","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1056\/NEJMoa2106391","volume":"385","author":"TK Choueiri","year":"2021","unstructured":"Choueiri TK, Tomczak P, Park SH et al (2021) Adjuvant Pembrolizumab after Nephrectomy in Renal-Cell Carcinoma. N Engl J Med 385(8):683\u2013694. https:\/\/doi.org\/10.1056\/NEJMoa2106391","journal-title":"N Engl J Med"},{"issue":"15","key":"6684_CR70","doi-asserted-by":"publisher","first-page":"1359","DOI":"10.1056\/NEJMoa2312695","volume":"390","author":"TK Choueiri","year":"2024","unstructured":"Choueiri TK, Tomczak P, Park SH et al (2024) Overall Survival with Adjuvant Pembrolizumab in Renal-Cell Carcinoma. N Engl J Med 390(15):1359\u20131371. https:\/\/doi.org\/10.1056\/NEJMoa2312695","journal-title":"N Engl J Med"},{"key":"6684_CR71","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1016\/j.euros.2022.11.008","volume":"47","author":"L Marconi","year":"2023","unstructured":"Marconi L, Kuusk T, Capitanio U et al (2023) Local treatment of recurrent renal cell carcinoma may have a significant survival effect across all risk-of-recurrence groups. Eur Urol Open Sci 47:65\u201372. https:\/\/doi.org\/10.1016\/j.euros.2022.11.008","journal-title":"Eur Urol Open Sci"},{"key":"6684_CR72","doi-asserted-by":"publisher","unstructured":"A Prospective Study of Stereotactic Body Radiation Therapy in Oligometastatic Renal Cell Carcinoma (2025) Int J Radiat Oncol Published online May 30. https:\/\/doi.org\/10.1016\/j.ijrobp.2025.05.059","DOI":"10.1016\/j.ijrobp.2025.05.059"},{"issue":"6","key":"6684_CR73","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1016\/S1470-2045(26)00091-4","volume":"27","author":"S Siva","year":"2026","unstructured":"Siva S, Pryor D, Martin J et al (2026) Long-term outcomes of stereotactic ablative body radiotherapy for primary kidney cancer (TROG 15.03 FASTRACK II): a multicentre, non-randomised, phase 2 study. Lancet Oncol 27(6):711\u2013720. https:\/\/doi.org\/10.1016\/S1470-2045(26)00091-4","journal-title":"Lancet Oncol"},{"issue":"6","key":"6684_CR74","doi-asserted-by":"publisher","first-page":"721","DOI":"10.1016\/S1470-2045(26)00170-1","volume":"27","author":"S Siva","year":"2026","unstructured":"Siva S, Ali M, Hardcastle N et al (2026) Ultra-hypofractionated stereotactic ablative body radiotherapy for primary renal cell carcinoma: 5-year outcomes from a pooled analysis of the FASTRACK trials. Lancet Oncol 27(6):721\u2013728. https:\/\/doi.org\/10.1016\/S1470-2045(26)00170-1","journal-title":"Lancet Oncol"},{"issue":"12","key":"6684_CR75","doi-asserted-by":"publisher","first-page":"1508","DOI":"10.1016\/S1470-2045(22)00656-8","volume":"23","author":"S Siva","year":"2022","unstructured":"Siva S, Ali M, Correa RJM et al (2022) 5-year outcomes after stereotactic ablative body radiotherapy for primary renal cell carcinoma: an individual patient data meta-analysis from IROCK (the International Radiosurgery Consortium of the Kidney). Lancet Oncol 23(12):1508\u20131516. https:\/\/doi.org\/10.1016\/S1470-2045(22)00656-8","journal-title":"Lancet Oncol"},{"issue":"1","key":"6684_CR76","doi-asserted-by":"publisher","first-page":"e18","DOI":"10.1016\/S1470-2045(23)00513-2","volume":"25","author":"S Siva","year":"2024","unstructured":"Siva S, Louie AV, Kotecha R et al (2024) Stereotactic body radiotherapy for primary renal cell carcinoma: a systematic review and practice guideline from the International Society of Stereotactic Radiosurgery (ISRS). Lancet Oncol 25(1):e18\u2013e28. https:\/\/doi.org\/10.1016\/S1470-2045(23)00513-2","journal-title":"Lancet Oncol"},{"issue":"6","key":"6684_CR77","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1007\/s10585-021-10131-w","volume":"38","author":"C Franzese","year":"2021","unstructured":"Franzese C, Marvaso G, Francolini G et al (2021) The role of stereotactic body radiation therapy and its integration with systemic therapies in metastatic kidney cancer: a multicenter study on behalf of the AIRO (Italian Association of Radiotherapy and Clinical Oncology) genitourinary study group. Clin Exp Metastasis 38(6):527\u2013537. https:\/\/doi.org\/10.1007\/s10585-021-10131-w","journal-title":"Clin Exp Metastasis"},{"issue":"5","key":"6684_CR78","doi-asserted-by":"publisher","first-page":"1416","DOI":"10.1016\/j.euo.2025.05.012","volume":"8","author":"A Pecoraro","year":"2025","unstructured":"Pecoraro A, Costagli S, Marandino L et al (2025) Quality Indicators for Renal Cancer Care: A Systematic Review. Eur Urol Oncol 8(5):1416\u20131427. https:\/\/doi.org\/10.1016\/j.euo.2025.05.012","journal-title":"Eur Urol Oncol"},{"issue":"4","key":"6684_CR79","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1016\/j.euo.2020.02.001","volume":"3","author":"Y Abu-Ghanem","year":"2020","unstructured":"Abu-Ghanem Y, Fern\u00e1ndez-Pello S, Bex A et al (2020) Limitations of Available Studies Prevent Reliable Comparison Between Tumour Ablation and Partial Nephrectomy for Patients with Localised Renal Masses: A Systematic Review from the European Association of Urology Renal Cell Cancer Guideline Panel. Eur Urol Oncol 3(4):433\u2013452. https:\/\/doi.org\/10.1016\/j.euo.2020.02.001","journal-title":"Eur Urol Oncol"},{"key":"6684_CR80","doi-asserted-by":"publisher","first-page":"1","DOI":"10.48193\/4s2h3424","volume":"84","author":"GAF Candia","year":"2024","unstructured":"Candia GAF, Camean J, Jaunarena J, Chemi J, Bachur RV, Villoldo G (2024) Complete laparoscopic management of locally recurrent renal cell carcinoma after radical nephrectomy. Revista Mexicana de Urolog\u00eda 84:1\u20139. https:\/\/doi.org\/10.48193\/4s2h3424","journal-title":"Revista Mexicana de Urolog\u00eda"},{"key":"6684_CR81","doi-asserted-by":"publisher","first-page":"11.e1","DOI":"10.1016\/j.urolonc.2017.08.021","volume":"36","author":"R Herout","year":"2018","unstructured":"Herout R, Graff J, Borkowetz A, Zastrow S, Leike S, Koch R et al (2018) Surgical resection of locally recurrent renal cell carcinoma after nephrectomy: oncological outcome and predictors of survival. Urol Oncol 36:11.e1-11.e6. https:\/\/doi.org\/10.1016\/j.urolonc.2017.08.021","journal-title":"Urol Oncol"},{"key":"6684_CR82","doi-asserted-by":"publisher","first-page":"2044","DOI":"10.1016\/j.juro.2009.01.043","volume":"181","author":"V Margulis","year":"2009","unstructured":"Margulis V, McDonald M, Tamboli P, Swanson DA, Wood CG (2009) Predictors of oncological outcome after resection of locally recurrent renal cell carcinoma. J Urol 181:2044\u201351. https:\/\/doi.org\/10.1016\/j.juro.2009.01.043","journal-title":"J Urol"},{"key":"6684_CR83","doi-asserted-by":"publisher","first-page":"434e17","DOI":"10.1016\/j.urolonc.2023.07.010","volume":"41","author":"J Huang","year":"2023","unstructured":"Huang J, Su R, Zhang C, Bao Y, Hu X, Ye X et al (2023) Comparative analysis of salvage partial nephrectomy versus radical nephrectomy after the failure of initial partial nephrectomy. Urol Oncol 41:434e17. 434.e25https:\/\/doi.org\/10.1016\/j.urolonc.2023.07.010","journal-title":"Urol Oncol"},{"key":"6684_CR84","doi-asserted-by":"publisher","DOI":"10.1016\/j.juro.2016.02.185","author":"A Antonelli","year":"2016","unstructured":"Antonelli A, Sodano M, Furlan M, Tardanico R, Fisogni S, Carobbio F (2016) Features and prognosis of renal relapse after partial nephrectomy MP41-18 pathogenesis. J Urol. https:\/\/doi.org\/10.1016\/j.juro.2016.02.185","journal-title":"J Urol"},{"key":"6684_CR85","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1016\/j.juro.2008.03.030","volume":"180","author":"A Johnson","year":"2008","unstructured":"Johnson A, Sudarshan S, Liu J, Linehan WM, Pinto PA, Bratslavsky G (2008) Feasibility and outcomes of repeat partial nephrectomy. J Urol 180:89\u201393 discussion 93. https:\/\/doi.org\/10.1016\/j.juro.2008.03.030","journal-title":"J Urol"},{"key":"6684_CR86","doi-asserted-by":"publisher","first-page":"209","DOI":"10.23736\/S2724-6051.22.04693-6","volume":"74","author":"G Margue","year":"2022","unstructured":"Margue G, Michiels C, Allenet C, Dupitout L, Ricard S, Jambon E et al (2022) Feasibility of salvage robotic partial nephrectomy after ablative treatment failure (UroCCR-62 study). Minerva Urol Nephrol 74:209\u2013215. https:\/\/doi.org\/10.23736\/S2724-6051.22.04693-6","journal-title":"Minerva Urol Nephrol"},{"key":"6684_CR87","doi-asserted-by":"publisher","first-page":"3269","DOI":"10.3390\/cancers17193269","volume":"17","author":"A Porreca","year":"2025","unstructured":"Porreca A, Marino F, De Marchi D, Giampaoli M, D\u2019Agostino D, Simonetti F et al (2025) Local Recurrence After Nephron Surgery: What to Do? An Italian Multicentric Registry. Cancers 17:3269. https:\/\/doi.org\/10.3390\/cancers17193269","journal-title":"Cancers"},{"key":"6684_CR88","doi-asserted-by":"publisher","DOI":"10.1097\/JU.0000000000003263.09","author":"S Saini","year":"2023","unstructured":"Saini S, O\u2019Rourke T, Thakker P, Hemal A, V05-09 ROBOT-ASSISTED PARTIAL NEPHRECTOMY FOR NEW OR RECURRENT TUMOR IN PATIENT WITH PRIOR PARTIAL NEPHRECTOMY OR TUMOR ABLATION (2023) J Urol. https:\/\/doi.org\/10.1097\/JU.0000000000003263.09","journal-title":"J Urol"},{"key":"6684_CR89","doi-asserted-by":"publisher","DOI":"10.1016\/j.juro.2017.02.521","author":"P Capogrosso","year":"2017","unstructured":"Capogrosso P, Barret E, Nunes-Silva I, Sanchez-Salas R, Rozet F, Larcher A et al (2017) MP16-15 NATURAL HISTORY OF SURGICALLY TREATED LOCAL RECURRENCE AFTER NEPHRECTOMY. J Urol. https:\/\/doi.org\/10.1016\/j.juro.2017.02.521","journal-title":"J Urol"},{"key":"6684_CR90","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1590\/S1677-5538.IBJU.2015.01.20","volume":"41","author":"FG Abarzua-Cabezas","year":"2015","unstructured":"Abarzua-Cabezas FG, Sverrisson E, De La Cruz R, Spiess PE, Haddock P, Sexton WJ (2015) Oncological and functional outcomes of salvage renal surgery following failed primary intervention for renal cell carcinoma. Int Braz J Urol 41:147\u201354. https:\/\/doi.org\/10.1590\/S1677-5538.IBJU.2015.01.20","journal-title":"Int Braz J Urol"},{"key":"6684_CR91","doi-asserted-by":"publisher","unstructured":"Riedl P, Habl, Hohenfellner UP-01.204 Surgery\u2009+\u2009Intraoperative Radiotherapy (IORT) + Additive External Beam Radiation: A Promising Option for Treatment of Locally Recurrent Renal Cell Carcinoma (RCC)? Urology 2011;2088:A1. https:\/\/doi.org\/10.1016\/j.urology.2011.07.754","DOI":"10.1016\/j.urology.2011.07.754"},{"key":"6684_CR92","doi-asserted-by":"publisher","DOI":"10.1097\/JU.0000000000003345.06","author":"A Das","year":"2023","unstructured":"Das A, Shapiro D, Borza T, Wells S, Hinshaw L, Ziemlewicz T, PD40-06 COMPARING ONCOLOGIC OUTCOMES BETWEEN SURGERY AND MICROWAVE ABLATION FOR RENAL MASSES BETWEEN 3 AND 7 CM et al (2023) J Urol. https:\/\/doi.org\/10.1097\/JU.0000000000003345.06","journal-title":"J Urol"},{"key":"6684_CR93","doi-asserted-by":"crossref","unstructured":"Yanagisawa T, Miki J, Sano T, Otsuka T, Enei Y, Iwatani K et al (2019) PD51-11 utility of salvage percutaneous cryoablation for locally recurrence rcc after primary cryoablation. J Urol","DOI":"10.1097\/01.JU.0000556955.92159.54"}],"container-title":["World Journal of Urology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00345-026-06684-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00345-026-06684-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00345-026-06684-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,16]],"date-time":"2026-08-16T06:29:57Z","timestamp":1786861797000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00345-026-06684-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,16]]},"references-count":93,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["6684"],"URL":"https:\/\/doi.org\/10.1007\/s00345-026-06684-8","relation":{},"ISSN":["1433-8726"],"issn-type":[{"value":"1433-8726","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,16]]},"assertion":[{"value":"15 July 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 August 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 August 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Shahrokh F. Shariat reports receiving honoraria from Astellas, AstraZeneca, BMS, Ferring, Ipsen, Janssen, MSD, Olympus, Pfizer, Roche, and Takeda; having a consulting or advisory role in Astellas, AstraZeneca, BMS, Ferring, Ipsen, Janssen, MSD, Olympus, Pfizer, Pierre Fabre, Roche, and Takeda; and being in the speakers\u2019 bureau of Astellas, Astra Zeneca, Bayer, BMS, Ferring, Ipsen, Janssen, MSD, Olympus, Pfizer, Richard Wolf, Roche, and Takeda. The remaining authors have nothing to disclose.","order":1,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Ethics declaration","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"568"}}